Drug Pipeline

Alirocumab Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
9
Active Studies
6
Recruiting
1
Phase 3
7
Top Sponsors
4
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-11 NCT07477704
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult…
Recruitment opened
2026-06-11 NCT07477704
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult…
Trial sites expanded: 0 -> 6 locations
2026-06-11 NCT07477704
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult…
date change Primary completion pushed: 2026-10-20 -> 2026-12-29
2026-06-03 NCT07581808
Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention
Recruitment opened
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-05-29 NCT07615166 Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in… Active, Not Recruiting
2026-05-29 NCT07615179 Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD) Active, Not Recruiting
2026-05-14 NCT07586540 Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque Phase 3 Not Yet Recruiting
Active Studies by Phase
Phase 4
2
Phase 3
1
Phase 2
1
Phase 1
1
Not specified
4
Active Trials
NCT IDTitleConditionStatus
Phase 4
NCT05292404 Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction Acute Myocardial Infarction Recruiting
NCT07581808 Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention Hypercholesterolemia Recruiting
Phase 3
NCT07586540 Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque Carotid Stenosis Not Yet Recruiting
Phase 2
NCT07477704 A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult… Hypercholesterolemia Recruiting
Phase 1
NCT04781322 Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers Alcohol Associated Liver Disease Recruiting
Not specified
NCT05430828 Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in… Hypercholesterolemia Recruiting
NCT07375225 Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in… Hypercholesterolaemia Recruiting
NCT07615166 Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in… Atherosclerotic Cardiovascular Disease Active, Not Recruiting
NCT07615179 Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD) Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events Active, Not Recruiting
Sponsors Running Alirocumab Trials
Disease Areas
Get alerts when Alirocumab trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free